Cassava Sciences, Inc. (SAVA) |
| 3.74 -0.45 (-10.74%) 10-10 16:00 |
| Open: | 4.25 |
| High: | 4.28 |
| Low: | 3.71 |
| Volume: | 4,036,582 |
| Market Cap: | 181(M) |
| PE Ratio: | -1.42 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 5.00 |
| Resistance 1: | 4.28 |
| Pivot price: | 3.35 |
| Support 1: | 2.90 |
| Support 2: | 2.04 |
| 52w High: | 33.98 |
| 52w Low: | 1.15 |
Financials
| EPS | -2.630 |
| Book Value | 1.820 |
| PEG Ratio | 0.00 |
| Gross Profit | -1.180 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -29.7 |
| Return on Equity (ttm) | -88.9 |
Company news
Mon, 06 Oct 2025
Cassava Sciences (SAVA): Lucid Capital Markets Initiates Coverage with Buy Rating | SAVA Stock News - GuruFocus
Sat, 27 Sep 2025
What Does Cassava Sciences (SAVA) CEO’s Insider Buy Reveal About Its Post-Alzheimer’s Strategy? - Sahm
Thu, 25 Sep 2025
Cassava Sciences: Fundamentals Update After Big Move On Insider Purchases (NASDAQ:SAVA) - Seeking Alpha
Thu, 14 Aug 2025
Cassava Sciences Advances Simufilam Development for TSC-Related Epilepsy and Reports Financial Results for Q2 2025 | SAVA Stock News - Quiver Quantitative
Mon, 04 Aug 2025
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - GlobeNewswire
Mon, 30 Jun 2025
Cassava Sciences Reveals Promising Simufilam Preclinical Data - TipRanks
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
